OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Seymour on the Importance of Targeted Therapy in CLL

September 13th 2023

John Seymour, MBBS, FRACP, PhD, discusses the importance of targeted therapy in patients with chronic lymphocytic leukemia.

Dr Hwang on Unmet Needs Remaining in Nonmetastatic Prostate Cancer

September 13th 2023

Clara Hwang, MD, discusses unmet needs in patients with nonmetastatic prostate cancer who then progress on novel agents and develop metastatic disease.

Dr Chari on the Selection of BCMA-Targeted Therapies Within Multiple Myeloma

September 13th 2023

Ajai Chari, MD, discusses important patient factors to consider when selecting between currently approved BCMA-targeted therapies for the treatment of patients with multiple myeloma.

Dr Westin on the Updated Treatment Paradigm in Second-Line LBCL

September 13th 2023

Jason R. Westin, MD, director, discusses how the approval of CAR T-cell therapies in the second-line setting has radically shifted preferred treatment approaches in relapsed/refractory large B-cell lymphoma.

Lung Cancer Experts Detail Challenges of Cisplatin/Carboplatin Shortages

September 13th 2023

Experts discuss the challenges of the ongoing cisplatin and carboplatin shortages in the United States and detail how they are adapting in their practices.

Dr Mehmi on the Rationale for Investigating Fianlimab/Cemiplimab in Advanced Melanoma

September 12th 2023

Inderjit Mehmi, MD, medical oncologist, discusses the rationale for investigating the combination of fianlimab and cemiplimab in patients who have advanced melanoma with poor-risk features

Dr Phadke on Sequencing ADCs in HR+/HER2– Breast Cancer

September 12th 2023

Sneha Phadke, DO, MPH, discusses sequencing treatment with antibody drug conjugates in hormone receptor-positive/HER2-negative breast cancer, as well as questions remaining within this space.

Dr Garcia-Manero on the Investigation of Luspatercept in Transfusion-Dependent MDS

September 12th 2023

Guillermo Garcia-Manero, MD, discusses the investigation of luspatercept vs epoetin alfa in patients with erythropoiesis-stimulating agent-naïve, lower-risk myelodysplastic syndromes and disease-related anemia who requires red blood cell transfusions.

Dr Fakih on the Significance of the PROSPECT Trial in Rectal Cancer

September 12th 2023

Marwan G. Fakih, MD, expands on long-term findings from the phase 2/3 PROSPECT trial and how these findings may influence the optimal use of nonoperative management strategies in locally advanced rectal cancer.

Dr Richardson on the Potential Significance of Mezigdomide in Relapsed/Refractory Multiple Myeloma

September 12th 2023

Paul G. Richardson, MD, discusses how the continued development of the novel agent mezigdomide could affect the treatment paradigm for patients who progressed on, and developed resistance to, other available BCMA-directed therapies.

Dr Leighl on Amivantamab in Advanced NSCLC With MET Exon 14 Skipping Mutations

September 12th 2023

Natasha B. Leighl, BSc, MMSc, MD, discusses efficacy findings with the EGFR/MET inhibitor amivantamab in patients with advanced non–small cell lung cancer harboring MET exon 14 skipping mutations.

Dr Leal on a PD-L1 Subgroup Analysis of the LUNAR Trial in mNSCLC

September 12th 2023

Ticiana Leal, MD, discusses the rationale for and findings from a PD-L1 subgroup analysis of the phase 3 LUNAR trial in patients with metastatic non–small cell lung cancer.

Dr Negrao on JDQ443 Plus TNO155 in Advanced, KRAS G12C–Mutated Solid Tumors

September 11th 2023

Marcelo Vailati Negrao, MD, discusses efficacy findings from the phase 1b/2 KontRASt-01 trial (NCT04699188) in patients with KRAS G12C–mutated solid tumors.

Dr Gadgeel on Adagrasib Monotherapy in KRAS G12C–Mutated NSCLC

September 11th 2023

Shirish M. Gadgeel, MD, discusses 2-year follow-up data from the phase 1/2 KRYSTAL-1 trial in patients with advanced or metastatic non–small cell lung cancer harboring KRAS G12C mutations.

Dr Seymour on the Curative Potential for FCR Treatment in CLL

September 11th 2023

John Seymour, MBBS, FRACP, PhD, discusses the curative potential of fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia.

Dr Miranda-Galvis on the Investigation of Social Determinants of Health in Hematologic Malignancies

September 11th 2023

Marisol Miranda-Galvis, DDS, MS, PhD, discusses the investigation of disparities in survival outcomes of patients with hematologic malignancies relating to social determinants.

Dr Hunter on the Current Treatment Landscape of JAK Inhibitor Treatment in Myelofibrosis

September 11th 2023

Anthony M Hunter, MD, discusses the current treatment landscape with JAK inhibitors in myelofibrosis.

Dr Costa on the Clinical Implications of the MASTER Trial in Multiple Myeloma

September 11th 2023

Luciano J. Costa, MD, PhD, discusses clinical implications derived from a final analysis of the phase 2 MASTER trial, which evaluated quadruplet induction therapy in multiple myeloma.

Dr Alumkal on Standard Treatment Options For Patients With HRD-Altered mCRPC

September 11th 2023

Joshi Alumkal, MD, discusses treatment options for patients with metastatic castrate-resistant prostate cancer harboring homologous recombination deficient alterations, including PARP inhibitors.

Dr Harpole on Perioperative Durvalumab Plus Chemotherapy in EGFR-Mutated NSCLC

September 11th 2023

David Harpole, MD, discusses findings from an exploratory analysis of the phase 3 AEGEAN trial in patients with EGFR-mutated non–small cell lung cancer.